Article info
PDFEditorial
Lessons from tofacitinib in patients with cardiovascular risk factors: increased pulmonary embolism or isolated (thrombotic) pulmonary occlusion rates?
- Correspondence to Professor Thomas Dörner, Department of Medicine/Rheumatology and Clinical Immunology, Charite Universitatsmedizin Berlin, Berlin 10117, Germany; thomas.doerner@charite.de
Citation
Lessons from tofacitinib in patients with cardiovascular risk factors: increased pulmonary embolism or isolated (thrombotic) pulmonary occlusion rates?
Publication history
- Received August 27, 2020
- Revised September 7, 2020
- Accepted September 8, 2020
- First published September 22, 2020.
Online issue publication
May 12, 2021
Article Versions
- Previous version (12 May 2021).
- You are viewing the most recent version of this article.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.